MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 11-05-2025
Charles River Laboratories International Operating Income 2011-2026 | CRL
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Charles River Laboratories International
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 227 M | 617 M | 651 M | 590 M | 433 M | 351 M | 331 M | 288 M | 238 M | 206 M | 178 M | 151 M | 166 M | 174 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 651 M | 151 M | 329 M |
Quarterly Operating Income Charles River Laboratories International
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 134 M | 100 M | 74.7 M | - | 117 M | 152 M | 126 M | - | 152 M | 165 M | 168 M | - | 151 M | 187 M | 149 M | - | 156 M | 138 M | 124 M | 129 M | 133 M | 76.8 M | 94.3 M | 109 M | 92.8 M | 79.8 M | 69.8 M | 102 M | 84.4 M | 76.7 M | 67.8 M | 62.8 M | 74.1 M | 81.7 M | 69.7 M | 69.1 M | 58.8 M | 58.1 M | 51.5 M | 52.3 M | 55.4 M | 55.7 M | 43 M | 40.8 M | 46.2 M | 51 M | 39.7 M | 24.6 M | 40.8 M | 43.2 M | 42.8 M | - | 37.7 M | 49.3 M | 43.7 M | - | 37.1 M | 53.3 M | 42.3 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 187 M | 24.6 M | 85.5 M |
Operating Income of other stocks in the Diagnostics research industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
-46 M | - | -6.23 % | $ 30.6 M |  Germany |
|
Akumin
AKU
|
-28.1 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Aspira Women's Health
AWH
|
-32.8 M | - | -6.19 % | $ 10.5 M |  USA |
 |
Biocept
BIOC
|
-32 M | - | -13.05 % | $ 7.29 M | USA |
 |
Brainsway Ltd.
BWAY
|
-5 M | - | - | $ 99.4 M |  Israel |
 |
Burning Rock Biotech Limited
BNR
|
-797 M | $ 29.8 | -3.87 % | $ 321 M |  China |
 |
Accelerate Diagnostics
AXDX
|
-14 M | - | -61.36 % | $ 2.46 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-25.9 M | - | - | $ 9.42 M | Israel |
 |
Co-Diagnostics
CODX
|
-42.7 M | - | - | $ 79.8 M | USA |
 |
BioNano Genomics
BNGO
|
-104 M | $ 1.13 | -3.54 % | $ 1.44 M | USA |
 |
Castle Biosciences
CSTL
|
8.67 M | - | - | $ 914 M | USA |
 |
Danaher Corporation
DHR
|
4.86 B | $ 219.93 | 0.09 % | $ 161 B | USA |
 |
Celcuity
CELC
|
-113 M | $ 104.25 | 0.08 % | $ 4.11 B | USA |
 |
Chembio Diagnostics
CEMI
|
-23.6 M | - | 0.22 % | $ 16.8 M | USA |
 |
DexCom
DXCM
|
598 M | - | - | $ 26.3 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
1.35 B | $ 209.75 | 2.09 % | $ 23.3 B | USA |
 |
Global Cord Blood Corporation
CO
|
609 M | - | - | $ 399 M | China |
 |
Enzo Biochem
ENZ
|
-12.4 M | - | -8.98 % | $ 14.8 K | USA |
 |
Genetron Holdings Limited
GTH
|
-518 M | - | 0.12 % | $ 80.1 M | China |
 |
CareDx, Inc
CDNA
|
-203 M | $ 19.51 | -5.18 % | $ 1.05 B | USA |
 |
DermTech
DMTK
|
-104 M | - | -11.32 % | $ 2.94 M | USA |
 |
DarioHealth Corp.
DRIO
|
-56.2 M | $ 11.07 | 1.37 % | $ 314 M | Israel |
 |
Heska Corporation
HSKA
|
-20.3 M | - | - | $ 1.31 B | USA |
 |
Exact Sciences Corporation
EXAS
|
-876 M | $ 103.42 | - | $ 19.2 B | USA |
 |
Interpace Biosciences
IDXG
|
8.11 M | $ 1.82 | - | $ 7.98 M | USA |
 |
Lantheus Holdings
LNTH
|
457 M | $ 67.04 | - | $ 4.64 B | USA |
 |
Fulgent Genetics
FLGT
|
-73.9 M | $ 23.02 | - | $ 696 M | USA |
 |
Guardant Health
GH
|
-444 M | $ 106.6 | 1.65 % | $ 13.1 B | USA |
 |
NeoGenomics
NEO
|
-92.1 M | $ 11.47 | - | $ 1.45 B | USA |
 |
QIAGEN N.V.
QGEN
|
97.7 M | - | - | $ 10.6 B |  Niderland |
 |
Natera
NTRA
|
-541 M | - | -0.5 % | $ 20.7 B | USA |
 |
OPKO Health
OPK
|
-152 M | $ 1.25 | 2.05 % | $ 868 M | USA |
 |
HTG Molecular Diagnostics
HTGM
|
-20.8 M | - | -20.0 % | $ 1.06 M | USA |
 |
Koninklijke Philips N.V.
PHG
|
553 M | $ 32.03 | -2.72 % | $ 20 B | Niderland |
 |
IDEXX Laboratories
IDXX
|
1.13 B | - | - | $ 53.5 B | USA |
 |
Illumina
ILMN
|
-833 M | $ 117.01 | -1.95 % | $ 18.6 B | USA |
 |
IQVIA Holdings
IQV
|
2.2 B | $ 176.27 | - | $ 32 B | USA |
|
Biodesix
BDSX
|
-34.5 M | - | - | $ 1.33 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
1.09 B | $ 289.4 | 1.75 % | $ 24.3 B | USA |
 |
ENDRA Life Sciences
NDRA
|
-10.8 M | $ 3.56 | -4.56 % | $ 1.91 M | USA |
 |
ICON Public Limited Company
ICLR
|
1.1 B | - | - | $ 11 B |  Irlanda |
 |
Biomerica
BMRA
|
-5.14 M | $ 2.23 | - | $ 5.12 M | USA |
 |
Bioventus
BVS
|
-81.7 M | $ 8.04 | - | $ 504 M | USA |